XELJANZ Market Drug Insight and Market Forecast - 2032

XELJANZ Market Drug Insight and Market Forecast − 2032

“XELJANZ Market Drug Insight and Market Forecast – 2032” report provides comprehensive insights about XELJANZ for Ulcerative Colitis (UC) in the seven major markets. A detailed picture of the XELJANZ for ulcerative colitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the XELJANZ for ulcerative colitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XELJANZ market forecast analysis for ulcerative colitis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in ulcerative colitis.

Drug Summary

XELJANZ (Tofacitinib) is an orally administered, small molecule, JAK inhibitor being developed by Pfizer to treat adults with moderately to severely active UC when medicines called TNF blockers do not work well or cannot be tolerated. XELJANZ is the first oral medication approved for chronic use in this indication. Tofacitinib works by blocking the body’s production of enzymes called Janus kinases (JAKs).

Dosage

Induction: XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily for eight weeks; evaluate patients and transition to maintenance therapy depending on therapeutic response. If needed, continue XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily for a maximum of 16 weeks. Discontinue XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily after 16 weeks if an adequate therapeutic response is not achieved.

Maintenance: XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. For patients with loss of response during maintenance treatment, XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily may be considered and limited to the shortest duration, considering the benefits and risks for the individual patient. Use the lowest effective dose needed to maintain response.

Mechanism of action

Tofacitinib is a JAK inhibitor. JAKs are intracellular enzymes that transmit signals from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers, and Activators of Transcription (STATs) modulate intracellular activity, including gene expression. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through the pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, and JAK2/JAK2). Tofacitinib inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively. However, the relevance of specific JAK combinations to therapeutic effectiveness is unknown.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the XELJANZ description, mechanism of action, dosage and administration, research and development activities in ulcerative colitis.

Elaborated details on XELJANZ regulatory milestones and other development activities have been provided in this report.

The report also highlights the XELJANZ research and development activities in ulcerative colitis across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around XELJANZ.

The report contains forecasted sales of for ulcerative colitis till 2032.

Comprehensive coverage of the late-stage emerging therapies for ulcerative colitis.

The report also features the SWOT analysis with analyst views for XELJANZ in ulcerative colitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XELJANZ Analytical Perspective by DelveInsight

In-depth XELJANZ Market Assessment

This report provides a detailed market assessment of XELJANZ for ulcerative colitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

XELJANZ Clinical Assessment

The report provides the clinical trials information of XELJANZ for ulcerative colitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for ulcerative colitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XELJANZ dominance.

Other emerging products for ulcerative colitis are expected to give tough market competition to XELJANZ and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XELJANZ in ulcerative colitis.

Our in-depth analysis of the forecasted sales data of XELJANZ from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XELJANZ in ulcerative colitis.

Key Questions

What is the product type, route of administration and mechanism of action of XELJANZ?

What is the clinical trial status of the study related to XELJANZ in ulcerative colitis and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XELJANZ development?

What are the key designations that have been granted to XELJANZ for ulcerative colitis?

What is the forecasted market scenario of XELJANZ for ulcerative colitis?

What are the forecasted sales of XELJANZ in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to XELJANZ for ulcerative colitis?

Which are the late-stage emerging therapies under development for the treatment of ulcerative colitis?